These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1. Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708 [TBL] [Abstract][Full Text] [Related]
9. The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5. Shuai H; Chan JF; Hu B; Chai Y; Yoon C; Liu H; Liu Y; Shi J; Zhu T; Hu JC; Hu YF; Hou Y; Huang X; Yuen TT; Wang Y; Zhang J; Xia Y; Chen LL; Cai JP; Zhang AJ; Yuan S; Zhou J; Zhang BZ; Huang JD; Yuen KY; To KK; Chu H EBioMedicine; 2023 Sep; 95():104753. PubMed ID: 37579626 [TBL] [Abstract][Full Text] [Related]
10. Virological and Mitochondriopathogical Characteristics of the SARS-CoV-2 Omicron XBB.1.16 Spike. Fang L; Kang X; Hong Q; Xue C; Pan L; Chen J; Tang C; Sun L; Xu X; Yuan J; Du Y; Xu A ACS Appl Mater Interfaces; 2024 Jun; 16(23):29716-29727. PubMed ID: 38814480 [TBL] [Abstract][Full Text] [Related]
11. The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage. Liang R; Ye ZW; Ong CP; Qin Z; Xie Y; Fan Y; Tang K; Poon VK; Chan CC; Yang X; Cao H; Wang K; Sun H; Hu B; Cai JP; Luo C; Chik KK; Chu H; Zheng Y; Yuen KY; Chan JF; Jin DY; Yuan S Emerg Microbes Infect; 2022 Dec; 11(1):2093-2101. PubMed ID: 35943779 [TBL] [Abstract][Full Text] [Related]
12. Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant. Tsujino S; Deguchi S; Nomai T; Padilla-Blanco M; Plianchaisuk A; Wang L; Begum MM; Uriu K; Mizuma K; Nao N; Kojima I; Tsubo T; Li J; Matsumura Y; Nagao M; Oda Y; Tsuda M; Anraku Y; Kita S; Yajima H; Sasaki-Tabata K; Guo Z; Hinay AA; Yoshimatsu K; Yamamoto Y; Nagamoto T; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Nasser H; Jonathan M; Putri O; Kim Y; Chen L; Suzuki R; Tamura T; Maenaka K; Irie T; Matsuno K; Tanaka S; Ito J; Ikeda T; Takayama K; Zahradnik J; Hashiguchi T; Fukuhara T; Sato K; Microbiol Immunol; 2024 Jul; ():. PubMed ID: 38961765 [TBL] [Abstract][Full Text] [Related]
13. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern. Akkız H Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924 [TBL] [Abstract][Full Text] [Related]
14. Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant. Tamura T; Irie T; Deguchi S; Yajima H; Tsuda M; Nasser H; Mizuma K; Plianchaisuk A; Suzuki S; Uriu K; Begum MM; Shimizu R; Jonathan M; Suzuki R; Kondo T; Ito H; Kamiyama A; Yoshimatsu K; Shofa M; Hashimoto R; Anraku Y; Kimura KT; Kita S; Sasaki J; Sasaki-Tabata K; Maenaka K; Nao N; Wang L; Oda Y; ; Ikeda T; Saito A; Matsuno K; Ito J; Tanaka S; Sato K; Hashiguchi T; Takayama K; Fukuhara T Nat Commun; 2024 Feb; 15(1):1176. PubMed ID: 38332154 [TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors. Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632 [TBL] [Abstract][Full Text] [Related]
16. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo. Uraki R; Kiso M; Iwatsuki-Horimoto K; Yamayoshi S; Ito M; Chiba S; Sakai-Tagawa Y; Imai M; Kashima Y; Koga M; Fuwa N; Okumura N; Hojo M; Iwamoto N; Kato H; Nakajima H; Ohmagari N; Yotsuyanagi H; Suzuki Y; Kawaoka Y Cell Rep; 2023 Dec; 42(12):113580. PubMed ID: 38103202 [TBL] [Abstract][Full Text] [Related]
17. Comparative Analysis of Conformational Dynamics and Systematic Characterization of Cryptic Pockets in the SARS-CoV-2 Omicron BA.2, BA.2.75 and XBB.1 Spike Complexes with the ACE2 Host Receptor: Confluence of Binding and Structural Plasticity in Mediating Networks of Conserved Allosteric Sites. Alshahrani M; Gupta G; Xiao S; Tao P; Verkhivker G Viruses; 2023 Oct; 15(10):. PubMed ID: 37896850 [TBL] [Abstract][Full Text] [Related]
18. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants. Qu P; Xu K; Faraone JN; Goodarzi N; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Gumina RJ; Liu SL Cell; 2024 Feb; 187(3):585-595.e6. PubMed ID: 38194968 [TBL] [Abstract][Full Text] [Related]